Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin D and ER levels of expression and other clinicopathologic characteristics in breast cancers.

Current medical research and opinion·2026
Same author

Immune Profiling Identifies Inflammatory Signatures in Immune Checkpoint Inhibitor-Related Myocarditis.

JACC. CardioOncology·2026
Same author

Genomics of gastroesophageal junction adenocarcinomas and the Siewert classification.

Translational gastroenterology and hepatology·2026
Same author

Decision making in intrathecal therapy for leptomeningeal disease.

Oncology·2026
Same author

Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Regulation of p53 by Ubiquitination and Implications for Therapeutic Targeting in Colorectal Cancer.

Genes·2026
Same journal

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026
Same journal

Comment on comparator design in regional versus general anesthesia for ambulatory breast-conserving surgery.

Breast (Edinburgh, Scotland)·2026
Same journal

HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.

Breast (Edinburgh, Scotland)·2026
Same journal

Patient satisfaction following Goldilocks mastectomy in non-obese women: A pilot study.

Breast (Edinburgh, Scotland)·2026
Same journal

Concerns about anesthetic standardization and interpretability in the comparison of regional anesthesia with dexmedetomidine versus general anesthesia.

Breast (Edinburgh, Scotland)·2026
Same journal

Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Breast sarcomas: current and future perspectives.

Ioannis A Voutsadakis1, Khalil Zaman, Serge Leyvraz

  • 1Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ivoutsadakis@yahoo.com

Breast (Edinburgh, Scotland)
|March 15, 2011
PubMed
Summary
This summary is machine-generated.

Breast sarcomas are rare breast cancers requiring distinct diagnosis and multidisciplinary care. Molecular profiling is crucial for subtype differentiation and targeted therapies, especially for post-radiation cases.

More Related Videos

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Area of Science:

  • Oncology
  • Surgical Pathology
  • Radiotherapy

Background:

  • Breast sarcomas are rare neoplasms, distinct from common breast carcinomas.
  • Multidisciplinary treatment approaches, informed by general sarcoma paradigms, are essential.
  • Distinguishing sarcoma subtypes based on molecular characteristics is increasingly important.

Purpose of the Study:

  • To highlight the rarity and distinct nature of breast sarcomas.
  • To emphasize the need for molecular subtyping in breast sarcoma treatment.
  • To address the growing incidence of sarcomas developing after breast irradiation.

Main Methods:

  • Review of existing literature on breast sarcomas and general sarcoma treatment.
  • Analysis of the increasing incidence of radiation-induced breast sarcomas.
  • Discussion of molecular characteristics and targeted therapy development.

Main Results:

  • Breast sarcomas necessitate differentiation from breast carcinomas.
  • Molecular profiling aids in identifying subtypes with differential treatment sensitivities.
  • Post-irradiation sarcomas are an emerging clinical concern.

Conclusions:

  • Breast sarcomas require specialized, multidisciplinary management.
  • Targeted therapies based on molecular subtypes hold promise for breast sarcomas.
  • The rise in breast conservation and radiotherapy increases the risk of secondary breast sarcomas.